BWAY - Brainsway Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.76
-0.09 (-1.02%)
At close: 3:24PM EDT
Stock chart is not supported by your current browser
Previous Close8.85
Open8.85
Bid8.61 x 1100
Ask8.83 x 1400
Day's Range8.56 - 8.85
52 Week Range8.00 - 12.39
Volume2,380
Avg. Volume7,570
Market Cap94.726M
Beta (3Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-1.03
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.69
Trade prices are not sourced from all markets
  • GlobeNewswire

    Family Wellness Center of Norman Hosts Open House to Introduce Newly Offered FDA-Cleared Deep TMS Helmet to Treat Major Depressive Disorder (MDD)

    Family Wellness Center of Norman, a full-service mental health clinic with advanced treatments for mental health disorders, announced today that it will host an open house on Wednesday, Oct. 23 from 4:00 p.m. - 6:00 p.m. The event will feature a demonstration of BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of major depressive disorder (MDD) and will offer the public a chance to meet the staff at the clinic. “Patients with MDD often find themselves resistant to traditional treatments such as medication or therapy,” said Susan Thompson APRN-CNP, psychiatric nurse practitioner and owner at Family Wellness Center of Norman.

  • GlobeNewswire

    BrainsWay Announces Innovative Deep Transcranial Magnetic Stimulation System Showcase Presentation at this Year’s Psych Congress Meeting

    BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, announced today they will be hosting “Advances in Neuromodulation for the Treatment of Neuropsychiatric Conditions”, an innovation showcase on their deep transcranial magnetic stimulation (dTMS) device, as well as other educational activities, during the Psych Congress Meeting being held from October 3-6 in San Diego, CA. Manish Sheth, MD, Ph.D., from Achieve TMS will be presenting at the innovation showcase and will discuss key advances in neuromodulation, such as dTMS, to treat a number of neuropsychiatric conditions, including Major Depressive Disorder (MDD) as well as Obsessive Compulsive Disorder (OCD).

  • GlobeNewswire

    Achieve TMS East Celebrates the Opening of a New Office in West Hartford, Connecticut

    WEST HARTFORD, Conn., Sept. 24, 2019 -- Achieve TMS East,​ New England’s largest provider of Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for the treatment of.

  • GlobeNewswire

    BrainsWay Announces Further Leadership Transition to U.S.

    JERUSALEM and HACKENSACK, N.J., Sept. 19, 2019 -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced, non-invasive.

  • GlobeNewswire

    Square Medical Group is Now Offering Mental Health Technology for Major Depressive Disorder (MDD) in Offices Across Massachusetts

    Square Medical Group, an integrated, multidisciplinary private group practice providing a full-range of outpatient mental health and chemical dependency services, is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for Major Depressive Disorder (MDD) at their locations in Watertown, Concord, Weymouth, and most recently, Danvers. “Square Medical Group’s unique value is our ability to provide the region’s most extensive continuum of care for our patients,” said Dr. Natalie L. Lender, MD, chief medical officer at Square Medical Group.

  • GlobeNewswire

    Catalyst Psychiatry Now Offering Mental Health Technology for Patients with Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD) in Corvallis

    Catalyst Psychiatry, a provider of mental health services in Oregon, is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for patients with Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD). Catalyst Psychiatry has been operating in Corvallis since 2014, and has since established itself as one of the premier mental health providers in the area by offering the latest technologies to the community.

  • GlobeNewswire

    Brainsway Reports Second Quarter 2019 Financial Results and Operational Highlights

    JERUSALEM, Israel and HACKENSACK, N.J., Aug. 26, 2019 -- Brainsway Ltd. (NASDAQ & TASE: BWAY) (“Brainsway” or the “Company”), a global leader in the advanced non-invasive.

  • ACCESSWIRE

    Brainsway Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Brainsway Ltd. (NASDAQ: BWAY ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 26, 2019 at 8:00 AM Eastern ...

  • GlobeNewswire

    BrainsWay Ltd. to Host Second Quarter 2019 Financial Results Conference Call on August 26, 2019

    BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its second quarter 2019 financial results and operational highlights on Monday, August 26, 2019. The Company will host a conference call on Monday, August 26, 2019 at 8:00 a.m. Eastern Time to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/financial-calendar.

  • GlobeNewswire

    New York Psychiatrist, Dr. Aleksandra Krunic, Introduces Groundbreaking FDA-Cleared Helmet to Treat Obsessive-Compulsive Disorder (OCD)

    Dr. Aleksandra Krunic, head of Child and Adult Clinical Psychiatry New York, a top psychiatric clinic serving patients in Long Island and New York City with a variety of advanced treatments for mental health disorders, announced today that the company will be introducing BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of Obsessive-Compulsive Disorder (OCD).

  • GlobeNewswire

    Achieve TMS East Celebrates the Opening of its Haverhill Location July 25, 2019

    Achieve TMS East, Massachusetts’ largest provider of deep TMS therapy for the treatment of Depression and OCD, is pleased to announce the opening of its newest center in Haverhill, MA. Achieve TMS East will be celebrating the opening of its Haverhill office with a Ribbon Cutting Ceremony and Open House on Friday, August 9, from 12:00 – 1:30 pm at 145 South Main Street, Suite 1C, Haverhill, MA 01835. Among the distinguished guests will be, Achieve TMS East Psychiatrist, Dr. Renee Snow, Achieve TMS East’s Director of Marketing, Anita Taylor and members of the Merrimack Chamber of Commerce.

  • GlobeNewswire

    Groundbreaking Study Demonstrates Advantages of BrainsWay Deep TMS in Treating Major Depressive Disorder

    BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, today announced the publication of a third-party study which demonstrated that Deep Transcranial Magnetic Stimulation (dTMS) plus standard medication was significantly more effective at reducing depression levels among  Major Depressive Disorder (MDD) patients compared with standard medication alone. “This is an important study, because it provides the first head-to-head comparison of two different technologies that use transcranial magnetic stimulation (TMS) to treat depression,” said Markus Heilig, MD, PhD, a Professor of Psychiatry at Linköping University. The results appear in the July 2019 issue of the Journal of Psychiatric Research.

  • GlobeNewswire

    New Data Published in American Journal of Psychiatry Further Substantiates BrainsWay’s Deep TMS System for the Treatment of Patients with Obsessive Compulsive Disorder

    BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced, non-invasive treatment of brain disorders, today announced new data from an article published in the last issue of the American Journal of Psychiatry demonstrating that its Deep TMS (dTMS) System showed a significant clinical benefit compared with placebo to treat Obsessive Compulsive Disorder (OCD) in a ~100-patient clinical trial (NCT02229903). OCD is a chronic and disabling disorder that affects ~1% of US adults. BrainsWay’s Deep TMS OCD treatment received De Novo clearance from the U.S. Food and Drug Administration (FDA) in August 2018 and is the only TMS platform that is FDA-cleared to treat OCD.

  • GlobeNewswire

    Chicago-based Psychiatrist, Dr. Fabian Carbonell, Debuts Innovative FDA-Cleared Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

    Dr. Fabian Carbonell is the first psychiatrist in Chicago to offer patients with depression and obsessive-compulsive disorder the ability to be treated with BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy. Deep TMS administers magnetic waves through a cushioned helmet to targeted deep structures of the brain that have a large impact on patients’ symptoms.

  • GlobeNewswire

    BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet for the Treatment of Obsessive-Compulsive Disorder

    Since receiving De Novo clearance from FDA in August 2018, the Company has shipped OCD coils to 100 sites across the U.S. JERUSALEM and HACKENSACK, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay” or the “Company”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation system (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), today announced the shipment of the 100th Deep TMS helmet for the treatment of OCD in adults since receiving De Novo clearance from the U.S. Food and Drug Administration for this indication in August 2018.

  • GlobeNewswire

    Brainsway Announces Changes to its Board of Directors

    Professor Abraham Zangen, Ph.D., a pioneering scientist in the field of TMS, has been appointed as a director. In addition, Ms. Eti Mitrany’s tenure as a director has been extended.  Professor Zangen’s and Ms. Mitrany’s tenure will expire at the Company’s next general meeting of shareholders.  Finally, Ms. Eynat Tsafrir has completed her tenure on Brainsway’s Board of Directors.

  • GlobeNewswire

    BrainsWay to Present at the 2019 Raymond James Life Sciences and MedTech Conference

    JERUSALEM and HACKENSACK, N.J., June 13, 2019 -- BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay” or the “Company”), a commercial stage medical device company focused on the.

  • GlobeNewswire

    “After the Smoke Clears” Brings Hope to Community on the Heels of Mental Health Awareness Month

    Calabasas Behavioral Health, a leading mental health service provider in Southern California, announced today that they are lending their time and expertise, in partnership with BrainsWay, the global leader in the advanced noninvasive treatment of brain disorders, to host “After the Smoke Clears.” The first of its kind event, free and open to the public, is designed to provide the local community with self-help tools, resources and support as they continue to recover from the Borderline Bar and Grill shooting and the Woolsey and Hill fires.

  • GlobeNewswire

    Brainsway Reports First Quarter 2019 Financial Results and Operational Highlights

    JERUSALEM and HACKENSACK, N.J., May 29, 2019 -- Brainsway Ltd. (NASDAQ & TASE: BWAY) (“Brainsway” or the “Company”), a commercial stage medical device company focused on.

  • GlobeNewswire

    Brainsway Ltd. to Host First Quarter 2019 Financial Results Conference Call on May 29, 2019

    Brainsway Ltd. (NASDAQ & TASE: BWAY) (“Brainsway”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation system (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), today announced that it will report its first quarter 2019 financial results and operational highlights on Wednesday, May 29, 2019. The Company will host a conference call on Wednesday, May 29, 2019 at 8:00 a.m. EDT to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/financial-calendar.

  • GlobeNewswire

    BrainsWay Announces its Multicenter Smoking Cessation Study Has Reached Target Enrollment

    BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”) today announced it reached target recruitment for its multicenter study assessing the safety and efficacy of its deep transcranial magnetic stimulation system (Deep TMS) intended for use as an aid in smoking cessation in patients suffering from chronic smoking addiction. Yaacov Michlin, President and Chief Executive Officer of BrainsWay, said, “We believe there is a considerable unmet need for a safe and efficient solution for cigarette addiction. BrainsWay’s Deep TMS device is designed to effectively stimulate deep and broad areas of the brain.

  • Carolina Partners in Mental HealthCare Expands Treatment Offerings to Include Revolutionary Mental Health Technology for Obsessive-Compulsive Disorder in North Carolina
    PR Newswire

    Carolina Partners in Mental HealthCare Expands Treatment Offerings to Include Revolutionary Mental Health Technology for Obsessive-Compulsive Disorder in North Carolina

    RALEIGH, N.C., May 13, 2019 /PRNewswire/ -- Carolina Partners, one of the most prominent mental and behavioral practices in the country, announced plans to offer patients access to BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for Obsessive-Compulsive Disorder (OCD). It will be one of the first practices in the area to provide Deep TMS for OCD, following its success in using Deep TMS to treat patients with depression.

  • GlobeNewswire

    Achieve TMS East Celebrates the Opening of its Dorchester Location

    Achieve TMS East, Massachusetts’ largest provider of Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for the treatment of Depression and Obsessive-Compulsive Disorder (OCD), is pleased to announce the opening of its newest center in Dorchester, MA. Achieve TMS East will be celebrating the opening of its Dorchester office with a Ribbon Cutting Ceremony and Open House on Friday, May 17, from 12:00 – 1:30 pm at the Carney Medical building located at 2110 Dorchester Avenue, Suite 308, Dorchester, MA 02124. Among the guests will be Marjorie Pierce, Director of Operations for Achieve TMS East.

  • GlobeNewswire

    Brainsway Ltd. Announces Closing of Initial Public Offering

    Brainsway Ltd. (NASDAQ: BWAY and TASE: BRIN) (“Brainsway”) today announced that it has closed its initial public offering of 2,500,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of Brainsway, at a public offering price of $11.00 per ADS. The gross proceeds to Brainsway from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are approximately $27.5 million. The underwriters have been granted an option to purchase up to an additional 375,000 ADSs offered by Brainsway for a period of 30 days after the pricing date.